InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: dcaf7 post# 287

Thursday, 03/09/2023 12:39:02 PM

Thursday, March 09, 2023 12:39:02 PM

Post# of 575
I think it would be very smart for APTO of out-license LUX for non-cancer indications once they get the dosing set. That said, I see huge synergy with combinations of LUX and TUSP in AML based on the complementary kinome inhibition profiles. Further LUX is likely to find a space in NHL, perhaps DLBCL, especially in combinations.

You need to get past thinking about the proteins as Flt3 inhibitors or BTK inhibitors. Those functions are subsets of their activities.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News